Vivek Paudyal

Dr. Vivek Paudyal

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2025 in Life
Verified
Journal Article
Open access
PDF file
MSMunish Sharma
Munish Sharma
VPVivek Paudyal
Vivek Paudyal
SSSaifullah Khalid Syed
Saifullah Khalid Syed
RTRubi Thapa
Rubi Thapa
NKNadeem Kassam
Nadeem Kassam
Salim SuraniSalim Surani
Salim Surani
Primary pulmonary hypertension (PPH), now known as pulmonary arterial hypertension (PAH), has induced significant treatment breakthroughs in the past decade. Treatment has focused on improving patient survival and quality of life, and delaying disease progression. Current therapies are categorized based on targeting different pathways known to contribute to PAH, including endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors (PDE-5 inhibitors), prostacyclin analogs, soluble guanylate cyclase stimulators, and activin signaling inhibitors such as Sotatercept. The latest addition to treatment options is soluble guanylate cyclase stimulators, such as Riociguat, which directly stimulates the nitric oxide pathway, facilitating vasodilation. Looking to the future, advancements in PAH treatment focus on precision medicine involving the sub-stratification of patients through a deep characterization of altered Transforming Growth Factor-β(TGF-β) signaling and molecular therapies. Gene therapy, targeting specific genetic mutations linked to PAH, and cell-based therapies, such as mesenchymal stem cells, are under investigation. Besides prevailing therapies, emerging PH treatments target growth factors and inflammation-modulating pathways, with ongoing trials assessing their long-term benefits and safety. Hence, this review explores current therapies that delay progression and improve survival, as well as future treatments with curative potential.

10 February 2025 in The Open Respiratory Medicine Journal
Verified
Journal Article
Open access
PDF file
VPVivek Paudyal
Vivek Paudyal
RTRubi Thapa
Rubi Thapa
SBSagarika Basnet
Sagarika Basnet
MSMunish Sharma
Munish Sharma
Salim SuraniSalim Surani
Salim Surani
JVJoseph Varon
Joseph Varon
Pulmonary Arterial Hypertension (PAH) is an uncommon condition with high mortality. It is an underrecognized condition both in developing and developed countries, especially in developing countries, due to a lack of advanced healthcare facilities and resources for timely diagnosis. More than half of the individuals diagnosed with PAH live less than five years after diagnosis. In recent years, tremendous advancements have been made in diagnostic and therapeutic strategies for PAH patients. Phosphodiesterase 5 (PDE5) inhibitors, endothelin receptor antagonists, and prostacyclin inhibitors in various forms (oral, inhaled, intravenous, or subcutaneous) have been the cornerstone of medical treatment. Atrial septostomy, heart and lung transplant, balloon pulmonary angioplasty, and pulmonary thromboendarterectomy are existing therapeutic options currently available. There has been a continuous effort to introduce newer therapies to improve life expectancy and modify disease. Newer therapies have shown promising results but require future data to guarantee long-term safety and efficacy. We aim to discuss a few of these critical updates in the constantly evolving field of PAH.

17 February 2025 in The Open Respiratory Medicine Journal
Verified
Journal Article
Open access
PDF file
RMRohit Masih
Rohit Masih
VPVivek Paudyal
Vivek Paudyal
YBYogendra Mani Basnet
Yogendra Mani Basnet
SSShaleen Sunesara
Shaleen Sunesara
MSMunish Sharma
Munish Sharma
Salim SuraniSalim Surani
Salim Surani
Pulmonary Arterial Hypertension (PAH) is a progressive vascular disease characterized by elevated Pulmonary Vascular Resistance (PVR) leading to Right Ventricular (RV) dysfunction and, ultimately, Right Heart Failure (RHF). Acute decompensation of PAH presents a life-threatening consequence marked by sudden worsening of clinical signs of right heart failure, systemic circulatory insufficiency, and multi-system organ failure. Clinicians are encountering more and more patients with PAH and RHF in the critical care units. These patients require admission and management in a critical care unit until they can be stabilized. The pathogenesis involves an imbalance between RV afterload and its adaptation capacity, ultimately resulting in RV dilation and failure. While the causes of acute decompensation remain subtle in many cases, infections, drug noncompliance, and pulmonary embolism are common culprits. Early identification of signs and symptoms of acute decompensation of RV failure, determination of possible etiology, and timely initiation of optimal treatment approaches are pivotal in avoiding detrimental outcomes. Optimization of pre-load and use of pulmonary vasodilators and inotropic agents are cornerstones of management. In refractory cases, mechanical circulatory support such as Extracorporeal Membrane Oxygenation (ECMO) or Right Ventricular Assist Devices (RVADs) may be necessary. Balloon Atrial Septostomy (BAS) serves as a bridge to definitive therapy, offering decompression of the right atrium and right ventricle. The prognosis of acute decompensated RV failure in PAH patients remains poor, highlighting the critical need for early diagnosis and intervention to improve outcomes. Currently, there are no strict standard guidelines to manage acute decompensated RV failure in PAH patients. We aim to revisit current evidence and practice trends in PAH and its acute decompensation.

15 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MSMunish Sharma
Munish Sharma
VPVivek Paudyal
Vivek Paudyal
SSSaifullah Khalid Syed
Saifullah Khalid Syed
RTRubi Thapa
Rubi Thapa
NKNadeem Kassam
Nadeem Kassam
Salim SuraniSalim Surani
Salim Surani
Primary pulmonary hypertension (PPH), now known as pulmonary arterial hypertension (PAH), has envisioned significant treatment breakthroughs in the past decade. Treatment has focused on improving patient survival and quality of life and delaying disease progression. Current therapies are categorized based on targeting different pathways known to contribute to PAH, including endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors (PDE-5 inhibitors), prostacyclin analogs, soluble guanylate cyclase stimulators, activin signaling inhibitors as Sotatercept. The latest addition to treatment options is soluble guanylate cyclase stimulators, such as Riociguat, which directly stimulates the nitric oxide pathway, facilitating vasodilation. Looking to the future, advancements in PAH treatment focus on precision medicine involving the sub-stratification of patients through a deep characterization of altered Transforming Growth Factor- β(TGF-β) signaling and molecular therapies. Gene therapy, targeting specific genetic mutations linked to PAH, and cell-based therapies, such as mesenchymal stem cells, are under investigation. Novel pharmacologic targets are also developing, including growth factors and inflammation-modulating pathways. Ongoing clinical trials aim to refine these emerging treatments and better understand their long-term benefits and safety profiles. This review will discuss the current therapies that help delay the progression and improve survival and future PAH treatments that hold potential for curative approaches targeting underlying disease mechanisms.